

To: The Board of Directors
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Suite1202, Yicheng Fortune Center,
22 Ronghua Middle Road,
Economic and Technological Development Zone,
Beijing,
PRC

23 October 2024

Dear Sirs/Madams,

We refer to the prospectus of Beijing Biostar Pharmaceuticals Co., Ltd. 北京華昊中天生物醫藥股份有限公司 (the “**Company**”) dated 23 October 2024(the “**Prospectus**”) in connection with the Company’s proposed Global Offering and the proposed Listing (both terms as defined in the Prospectus).

We hereby give, and confirm that we have not withdrawn, our consent to the issue of the Prospectus with the inclusion of our report and/or opinions and references to our name included in the form and context in which it respectively appears in the Prospectus.

We also consent to, and confirm that we have not withdrawn our consent to, a copy of this letter being made available on display as described in the section headed “Documents Delivered to The Registrar of Companies in Hong Kong” and “Documents Available on Display” in Appendix VIII to the Prospectus.

For and on behalf of
CCB International Capital Limited

A handwritten signature in blue ink, appearing to read 'KLau', positioned above a horizontal line.

Name: Kenneth Lau

Title: Executive Director

For and on behalf of
CCB International Capital Limited



Name: Jason Liu
Title: Vice President

To: The Board of Directors
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Suite1202, Yicheng Fortune Center,
22 Ronghua Middle Road,
Economic and Technological Development Zone,
Beijing,
PRC

23 October 2024

Dear Sirs/Madams,

We refer to the prospectus of Beijing Biostar Pharmaceuticals Co., Ltd. 北京華昊中天生物醫藥股份有限公司 (the “**Company**”) dated 23 October 2024 (the “**Prospectus**”) in connection with the Company’s proposed Global Offering and the proposed Listing (both terms as defined in the Prospectus).

We hereby give, and confirm that we have not withdrawn, our consent to the issue of the Prospectus with the inclusion of our report and/or opinions and references to our name included in the form and context in which it respectively appears in the Prospectus.

We also consent to, and confirm that we have not withdrawn our consent to, a copy of this letter being made available on display as described in the section headed “Documents Delivered to The Registrar of Companies in Hong Kong” and “Documents Available on Display” in Appendix VIII to the Prospectus.

For and on behalf of
**China Securities (International) Corporate
Finance Company Limited**

A handwritten signature in black ink, appearing to be 'Jason Li', written over a horizontal line.

Name: Jason Li

Title: Managing Director

For and on behalf of
**China Securities (International) Corporate
Finance Company Limited**



Name: Rick Wong

Title: Executive Director



KPMG
8th Floor, Prince's Building
Central, Hong Kong
G P O Box, Hong Kong
Telephone +852 2522 6022
Fax +852 2845 2588
Internet kpmg.com/cn

毕马威会计师事务所
香港中环遮打道10号
太子大厦8楼
香港邮政总局信箱50号
电话 +852 2522 6022
传真 +852 2845 2588
网址 kpmg.com/cn

The Board of Directors
Beijing Biostar Pharmaceuticals Co., Ltd.
No.88 Kechuang Sixth Street
Beijing Economic-Technological Development Zone
Beijing, PRC

Our ref FL/CDCP1

October 23, 2024

Dear Sirs

We refer to the prospectus dated October 23, 2024 in connection with the proposed initial listing of H shares of Beijing Biostar Pharmaceuticals Co., Ltd. (the "Company") on the Main Board of The Stock Exchange of Hong Kong Limited (the "Prospectus"), a copy of which is attached and stamped by us on its front cover for the purpose of identification.

We hereby consent to the inclusion of our accountants' report dated October 23, 2024 on the historical financial information for the years ended December 31, 2022, 2023 and the five months ended May 31, 2024 and our report dated October 23, 2024 on the pro forma financial information as at May 31, 2024 in the Prospectus, and the references to our name in the form and context in which they are included.



Yours faithfully

A handwritten signature in black ink that reads 'KPMG' in a stylized, cursive font.

Certified Public Accountants
Hong Kong

HNP LAW

October 23, 2024

To: The Board of Directors
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Suite1202, Yicheng Fortune Center,
22 Ronghua Middle Road,
Economic and Technological Development Zone,
Beijing, PRC

Dear Sirs/Madams,

We refer to the prospectus of Beijing Biostar Pharmaceuticals Co., Ltd. 北京華昊中天生物醫藥股份有限公司 (the “**Company**”) dated October 23, 2024 (the “**Prospectus**”) in connection with the Company’ s proposed Global Offering and the proposed Listing (both terms as defined in the Prospectus).

We hereby give, and confirm that we have not withdrawn, our consent to the issue of the Prospectus with the inclusion of our report and/or opinions and references to our name included in the form and context in which it respectively appears in the Prospectus.

We also consent to, and confirm that we have not withdrawn our consent to, a copy of our report and/or opinions and this letter being made available on display as described in the section headed “Documents Delivered to The Registrar of Companies in Hong Kong” and “Documents Available on Display” in Appendix VIII to the Prospectus.

HNP Law Firm, PLLC



Huaying Piao, Parnter

Expert Consent Letter to Beijing Biostar Pharmaceuticals Co., Ltd.

To: The Board of Directors
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Suite1202, Yicheng Fortune Center,
22 Ronghua Middle Road,
Economic and Technological Development Zone,
Beijing,
PRC

October 23, 2024

Dear Sirs/Madams,

We refer to the prospectus of Beijing Biostar Pharmaceuticals Co., Ltd. 北京華昊中天生物醫藥股份有限公司 (the “**Company**”) dated October 23, 2024 (the “**Prospectus**”) in connection with the Company’s proposed Global Offering and the proposed Listing (both terms as defined in the Prospectus).

We hereby give, and confirm that we have not withdrawn, our consent to the issue of the Prospectus with the inclusion of our report and/or opinions and references to our name included in the form and context in which it respectively appears in the Prospectus.

We also consent to, and confirm that we have not withdrawn our consent to, a copy of our report and/or opinions and this letter being made available on display as described in the section headed “Documents Delivered to The Registrar of Companies in Hong Kong” and “Documents Available on Display” in Appendix VIII to the Prospectus.

Expert Consent Letter to Beijing Biostar Pharmaceuticals Co., Ltd.

Yours faithfully,

For and on behalf of
Beijing DeHeng Law Offices

Yanli Sun

Name: Yanli Sun

Title: Partner

To: The Board of Directors
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Suite1202, Yicheng Fortune Center,
22 Ronghua Middle Road,
Economic and Technological Development Zone,
Beijing,
PRC

October 23, 2024

Dear Sirs/Madams,

We refer to the prospectus of Beijing Biostar Pharmaceuticals Co., Ltd. 北京華昊中天生物醫藥股份有限公司 (the “Company”) dated October 23, 2024 (the “Prospectus”) in connection with the Company’s proposed Global Offering and the proposed Listing (both terms as defined in the Prospectus).

We hereby give, and confirm that we have not withdrawn, our consent to the issue of the Prospectus with the inclusion of our report and/or opinions and references to our name included in the form and context in which it respectively appears in the Prospectus.

We also consent to, and confirm that we have not withdrawn our consent to, a copy of our report and/or opinions and this letter being made available on display as described in the section headed “Documents Delivered to The Registrar of Companies in Hong Kong” and “Documents Available on Display” in Appendix VIII to the Prospectus.

Yours faithfully,

For and on behalf of
Lung Tin Law Firm



Name: XIAOLEI LI
Title: Partner

To: The Board of Directors
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Suite1202, Yicheng Fortune Center,
22 Ronghua Middle Road,
Economic and Technological Development Zone,
Beijing,
PRC

October 23, 2024

Dear Sirs/Madams,


We refer to the prospectus of Beijing Biostar Pharmaceuticals Co., Ltd. 北京華昊中天生物醫藥股份有限公司 (the “**Company**”) dated October 23, 2024 (the “**Prospectus**”) in connection with the Company’s proposed Global Offering and the proposed Listing (both terms as defined in the Prospectus).

We hereby give, and confirm that we have not withdrawn, our consent to the issue of the Prospectus with the inclusion of our report and/or opinions and references to our name included in the form and context in which it respectively appears in the Prospectus.

We also consent to, and confirm that we have not withdrawn our consent to, a copy of our report and/or opinions and this letter being made available on display as described in the section headed “Documents Delivered to The Registrar of Companies in Hong Kong” and “Documents Available on Display” in Appendix VIII to the Prospectus.

Yours faithfully,

For and on behalf of
King & Wood Mallesons

A handwritten signature in black ink, appearing to read 'Tina TAI', is written over a horizontal line. The signature is stylized and cursive.

Name: Tina TAI
Title: Co-Head of Patent



CONSULTING & APPRAISAL

亞太評估

To: The Board of Directors
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Suite1202, Yicheng Fortune Center,
22 Ronghua Middle Road,
Economic and Technological Development Zone,
Beijing,
PRC

October 23, 2024

Dear Sirs/Madams,

We refer to the prospectus of Beijing Biostar Pharmaceuticals Co., Ltd. 北京華昊中天生物醫藥股份有限公司 (the “**Company**”) dated October 23, 2024 (the “**Prospectus**”) in connection with the Company’s proposed Global Offering and the proposed Listing (both terms as defined in the Prospectus).

We hereby give, and confirm that we have not withdrawn, our consent to the issue of the Prospectus with the inclusion of our report and/or opinions and references to our name included in the form and context in which it respectively appears in the Prospectus.

We also consent to, and confirm that we have not withdrawn our consent to, a copy of our report and/or opinions and this letter being made available on display as described in the section headed “Documents Delivered to The Registrar of Companies in Hong Kong” and “Documents Available on Display” in Appendix VIII to the Prospectus.



CONSULTING & APPRAISAL
亞太評估

Yours faithfully,

For and on behalf of
Asia-Pacific Consultant and Appraisal Limited

A handwritten signature in black ink, appearing to read 'D.G. Cheng', is written above a horizontal line.

David G.D. Cheng
MRICS
Executive Director

To: The Board of Directors
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Suite1202, Yicheng Fortune Center,
22 Ronghua Middle Road,
Economic and Technological Development Zone,
Beijing,
PRC

October 23, 2024

Dear Sirs/Madams,


We refer to the prospectus of Beijing Biostar Pharmaceuticals Co., Ltd. 北京華昊中天生物醫藥股份有限公司 (the “**Company**”) dated October 23, 2024 (the “**Prospectus**”) in connection with the Company’s proposed Global Offering and the proposed Listing (both terms as defined in the Prospectus).

We hereby give, and confirm that we have not withdrawn, our consent to the issue of the Prospectus with the inclusion of our report and/or opinions and references to our name included in the form and context in which it respectively appears in the Prospectus.

We also consent to, and confirm that we have not withdrawn our consent to, a copy of our report and/or opinions and this letter being made available on display as described in the section headed “Documents Delivered to The Registrar of Companies in Hong Kong” and “Documents Available on Display” in Appendix VIII to the Prospectus.

Yours faithfully,

For and on behalf of
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.



Name: Charles Lau

Title: Executive Director